News

February was a busy month for the FDA in the field of biosimilars:

 

  • On February 3, 2020, the FDA and FTC issued a joint statement regarding their enhanced collaboration to support the adoption of biosimilars and interchangeables.
  • On February 3, 2020, the FDA published a draft guidance,Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers.”  Comments will be accepted until April 2, 2020.
  • On February 3, 2020, the FDA and FTC announced a public workshop on a competitive marketplace for biosimilars, to take place on March 9, 2020.
  • On February 6, 2020, the FDA issued a draft guidance,Biosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed.”  Comments will be accepted until April 6, 2020.
  • On February 21, 2020, a final rule on the definition of “biological product” was published.  This rule defines “protein” as “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.”  The FDA is using this “bright line” approach to reduce uncertainty regarding whether products will be regulated as drugs or biological products.  Under the final definition, “insulin clearly is a ‘protein’ … because the total number of amino acids exceeds 40” and thus will be regulated as a biological product.
  • On February 21, 2020, the FDA issued frequently asked question documents for patients and health care providers relating to the transition of biological products approved under the Food, Drug, and Cosmetic Act, such as insulin and human growth hormone, from being regulated as drugs to being regulated as biological products, as of March 23, 2020.
  • On February 24, 2020, the FDA launched its revised version of the “Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations,” also known as the Purple Book, that is now searchable.  This initial phase of the searchable database includes information on licensed biosimilar and interchangeable products and their reference products.

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha